DK2261378T3 - Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membranfusogene kappeproteiner - Google Patents

Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membranfusogene kappeproteiner

Info

Publication number
DK2261378T3
DK2261378T3 DK10182056.1T DK10182056T DK2261378T3 DK 2261378 T3 DK2261378 T3 DK 2261378T3 DK 10182056 T DK10182056 T DK 10182056T DK 2261378 T3 DK2261378 T3 DK 2261378T3
Authority
DK
Denmark
Prior art keywords
fusion
virus
present
class
inhibiting
Prior art date
Application number
DK10182056.1T
Other languages
English (en)
Inventor
Robert F Garry
Russell B Wilson
Original Assignee
Univ Tulane
Autoimmune Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane, Autoimmune Technologies Llc filed Critical Univ Tulane
Application granted granted Critical
Publication of DK2261378T3 publication Critical patent/DK2261378T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
DK10182056.1T 2003-11-04 2004-11-03 Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membranfusogene kappeproteiner DK2261378T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51718103P 2003-11-04 2003-11-04
EP04810256A EP1692265B1 (en) 2003-11-04 2004-11-03 Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins

Publications (1)

Publication Number Publication Date
DK2261378T3 true DK2261378T3 (da) 2014-01-20

Family

ID=34572923

Family Applications (7)

Application Number Title Priority Date Filing Date
DK10182040.5T DK2261376T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
DK10182056.1T DK2261378T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membranfusogene kappeproteiner
DK10182018.1T DK2261375T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af viruscellefusion ved hæmning af funktionen af fusionsinitieringsområdet i RNA-vira med klasse I membranfusogene kappeproteiner
DK04810256.0T DK1692265T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
DK10182060.3T DK2261380T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
DK10182049.6T DK2261377T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membran-fusogene kappeproteiner
DK10181974.6T DK2261374T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hæmning af viruscellefusion ved hæmning af fusionsstartområdets funktion i RNA-virus med klasse 1 membran-fusiogene indhyllings-proteiner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10182040.5T DK2261376T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner

Family Applications After (5)

Application Number Title Priority Date Filing Date
DK10182018.1T DK2261375T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af viruscellefusion ved hæmning af funktionen af fusionsinitieringsområdet i RNA-vira med klasse I membranfusogene kappeproteiner
DK04810256.0T DK1692265T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
DK10182060.3T DK2261380T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA vira med klasse I membranfusogene indhyldningsproteiner
DK10182049.6T DK2261377T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membran-fusogene kappeproteiner
DK10181974.6T DK2261374T3 (da) 2003-11-04 2004-11-03 Fremgangsmåde til hæmning af viruscellefusion ved hæmning af fusionsstartområdets funktion i RNA-virus med klasse 1 membran-fusiogene indhyllings-proteiner

Country Status (13)

Country Link
US (5) US7491793B2 (da)
EP (7) EP2261380B1 (da)
JP (1) JP5008398B2 (da)
AT (1) ATE518967T1 (da)
AU (2) AU2004288218B2 (da)
BR (1) BRPI0416187A (da)
CA (1) CA2544848C (da)
DK (7) DK2261376T3 (da)
ES (7) ES2392891T3 (da)
HK (6) HK1152081A1 (da)
PL (4) PL2261378T3 (da)
PT (4) PT2261377E (da)
WO (1) WO2005044992A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392891T3 (es) 2003-11-04 2012-12-14 The Administrators Of The Tulane Educational Fund Procedimiento de prevención de la fusión virus célula inhibiendo la función de la región de iniciación de fusión de virus de ARN que tienen proteínas de envoltura fusogénicas de membrana de clase I
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US8222204B2 (en) * 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
ES2581381T3 (es) * 2007-06-25 2016-09-05 Autoimmune Technologies, Llc Composiciones y métodos de inhibición de la gripe
WO2009005783A1 (en) * 2007-06-28 2009-01-08 Blanchette Rockefeller Neurosciences Institute Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
US10138276B2 (en) 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
EP2516459A1 (en) * 2009-12-22 2012-10-31 Aarhus Universitet (University Of Aarhus) Bivalent molecules for hiv entry inhibition
EP2528622A2 (en) 2010-01-26 2012-12-05 The Regents of the University of Colorado Influenza virus epitopes templated into double-stranded coiled coils and use thereof in immunization
EP2536425B1 (en) * 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US20130289246A1 (en) * 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
US9060972B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
US10131695B2 (en) 2011-09-20 2018-11-20 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
US8999925B2 (en) * 2013-02-26 2015-04-07 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9649375B2 (en) * 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US10189878B2 (en) 2014-09-24 2019-01-29 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
US20230014151A1 (en) * 2019-09-04 2023-01-19 The Trustees Of Columbia University In The City Of New York Combination antiviral therapy for measles
US11479582B2 (en) 2020-10-16 2022-10-25 King Faisal University Anti-SARS-CoV-2 fusion peptides
JP2022116482A (ja) * 2021-01-29 2022-08-10 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1711888A (en) 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
US5747239A (en) 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5567805A (en) 1990-03-09 1996-10-22 Administrators Of The Tulane Educational Fund The cellular receptor for the CS3 peptide of human immunodeficiency virus
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6037348A (en) 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
JPH11209281A (ja) * 1998-01-21 1999-08-03 Daikin Ind Ltd ヘマグルチニン結合活性及びシアリダーゼ活性に対する阻害剤、及び、これを用いてウイルス又は微生物の感染を治療及び／又は予防する方法
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
JP4528989B2 (ja) * 1999-03-31 2010-08-25 学校法人慶應義塾 インフルエンザウイルス・ヘマグルチニン結合性ペプチド
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
WO2001016183A1 (en) * 1999-08-30 2001-03-08 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
WO2001059457A2 (en) 2000-02-10 2001-08-16 Panacos Pharmaceuticals, Inc. Assay for detection of viral fusion inhibitors
GB0022969D0 (en) 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
AU2001292944B2 (en) * 2000-09-22 2005-07-21 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
US7731975B2 (en) * 2001-01-31 2010-06-08 The United States Of America As Represented By The Secretary Of The Army Chimeric filovirus glycoprotein
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
JP4651213B2 (ja) * 2001-03-27 2011-03-16 株式会社グライコメディクス インフルエンザウイルス・ヘマグルチニン結合性ペプチド
KR100906102B1 (ko) * 2001-03-27 2009-07-07 사무엘 보고치 레플리킨 펩타이드 및 그의 이용
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
AU2003245729A1 (en) * 2002-06-27 2004-01-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US20070092936A1 (en) 2003-05-08 2007-04-26 Haynes Barton F Severe acute respiratory syndrome
WO2004111081A2 (en) * 2003-06-13 2004-12-23 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
AU2004259750A1 (en) 2003-07-21 2005-02-03 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Soluble fragments of the SARS-CoV spike glycoprotein
ES2392891T3 (es) 2003-11-04 2012-12-14 The Administrators Of The Tulane Educational Fund Procedimiento de prevención de la fusión virus célula inhibiendo la función de la región de iniciación de fusión de virus de ARN que tienen proteínas de envoltura fusogénicas de membrana de clase I

Also Published As

Publication number Publication date
EP2261376A2 (en) 2010-12-15
HK1152084A1 (en) 2012-02-17
BRPI0416187A (pt) 2007-01-23
EP2261374B1 (en) 2012-06-06
WO2005044992A3 (en) 2006-12-07
EP2261380A3 (en) 2011-02-23
US9056900B2 (en) 2015-06-16
PT2261378E (pt) 2013-12-09
EP2261380A2 (en) 2010-12-15
US20090264362A1 (en) 2009-10-22
CA2544848A1 (en) 2005-05-19
AU2010201046B2 (en) 2013-06-27
EP2261376B1 (en) 2013-07-10
DK1692265T3 (da) 2011-11-21
JP2007514408A (ja) 2007-06-07
US20120289458A1 (en) 2012-11-15
DK2261377T3 (da) 2014-01-06
WO2005044992A2 (en) 2005-05-19
PT2261377E (pt) 2013-11-29
AU2004288218B2 (en) 2009-12-24
EP2261380B1 (en) 2013-07-17
EP2261377B1 (en) 2013-10-02
HK1152081A1 (en) 2012-02-17
EP2261377A2 (en) 2010-12-15
US7491793B2 (en) 2009-02-17
EP2261376A3 (en) 2011-02-23
EP1692265A4 (en) 2007-08-29
DK2261376T3 (da) 2013-10-07
US20150239940A1 (en) 2015-08-27
EP2261378A2 (en) 2010-12-15
ES2427847T3 (es) 2013-11-04
EP1692265A2 (en) 2006-08-23
DK2261374T3 (da) 2012-09-10
CA2544848C (en) 2015-12-29
DK2261380T3 (da) 2013-10-07
PL1692265T3 (pl) 2011-12-30
HK1152086A1 (en) 2012-02-17
ES2392891T3 (es) 2012-12-14
HK1152085A1 (en) 2012-02-17
EP2261377A3 (en) 2011-05-18
US20060280754A1 (en) 2006-12-14
ES2437858T3 (es) 2014-01-14
ES2372633T3 (es) 2012-01-25
EP2261378A3 (en) 2011-06-15
HK1152082A1 (en) 2012-02-17
PL2261376T3 (pl) 2014-04-30
DK2261375T3 (da) 2013-04-22
US9725487B2 (en) 2017-08-08
PL2261377T3 (pl) 2014-03-31
EP2261375A3 (en) 2011-06-22
ATE518967T1 (de) 2011-08-15
AU2010201046A1 (en) 2010-04-08
EP2261374A3 (en) 2011-03-02
EP2261378B1 (en) 2013-10-09
PL2261378T3 (pl) 2014-03-31
ES2400456T3 (es) 2013-04-10
HK1152083A1 (en) 2012-02-17
PT1692265E (pt) 2011-10-11
EP2261374A2 (en) 2010-12-15
US8598116B2 (en) 2013-12-03
JP5008398B2 (ja) 2012-08-22
ES2435941T3 (es) 2013-12-26
AU2004288218A1 (en) 2005-05-19
PT2261376E (pt) 2013-09-23
US20140045743A1 (en) 2014-02-13
EP2261375A2 (en) 2010-12-15
EP2261375B1 (en) 2013-01-23
EP1692265B1 (en) 2011-08-03
ES2425600T3 (es) 2013-10-16

Similar Documents

Publication Publication Date Title
DK2261378T3 (da) Fremgangsmåde til hindring af virus:celle-fusion ved hæmning af funktionen af fusionsinitieringsregionen i RNA virus med klasse I membranfusogene kappeproteiner
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
NZ598000A (en) Composition for treating hbv infection
DK1644363T3 (da) Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
Rodamilans et al. Plant viral proteases: beyond the role of peptide cutters
WO2005007805A3 (en) ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING ssRNA VIRAL INFECTION
WO2003033657A3 (en) Antisense antiviral agent and method for treating ssrna viral infection
Albarino et al. Efficient reverse genetics generation of infectious Junin viruses differing in glycoprotein processing
NO20071162L (no) Heterosykliske antivirale forbindelser
ATE494373T2 (de) Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
WO2007084435A3 (en) Methods for treating hepatitis c
WO2005117908A3 (en) Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases
ATE505541T1 (de) Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai
TW200738626A (en) Methods for treating hepatitis C
TW200519210A (en) Hog cholera tissue culture live vaccine virus, the tissue culture method of the same and hog cholera tissue culture live vaccine comprising the same